Skip to main content
NIH funding notice PAR-25-270

NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)

Open. Closes November 13, 2026.

Posted
December 2, 2024
Close date
November 13, 2026
Activity codes
R33
Institutes taking part
NCCIH

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

  1. Reissues: PAR-24-116 NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
  2. 2 steps back: PAR-20-217 NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
  3. 3 steps back: PAR-18-828 NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
  4. 4 steps back: PAR-17-318 NCCIH Natural Product Phase I-IIa Clinical Trial Award (R33)
  5. 5 steps back: PAR-16-419 Exploratory Clinical Trials and Studies of Natural Products in NCCIH High Priority Research Topics (R33)
  6. 6 steps back: RFA-AT-16-002 Exploratory Clinical Trials of Natural Products in NCCIH High Priority Research Topics (R33)

Who won it before

6 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $3,200,337 in first-year total cost, median $520,881.

Most frequent study sections

  1. Special Emphasis Panel[ZAT1 MH (01)]4
  2. Special Emphasis Panel[ZAT1 SM (54)]1
  3. Special Emphasis Panel[ZAT1 YW (01)]1

Most frequent institutions

  1. IMMUNOGENICS, LLC1
  2. JOHNS HOPKINS UNIVERSITY1
  3. LOUISIANA STATE UNIV HSC SHREVEPORT1
  4. SOUTHERN METHODIST UNIVERSITY1
  5. UNIVERSITY OF FLORIDA1
Competing awards under PAR-25-270 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Specialized pro-resolving lipid mediators and treatment resistant depression1R33AT012329-01 · under PAR-20-217RAPAPORT, MARK HYMANUNIVERSITY OF UTAH, UT$579,633ZAT1
2023The potential of kava in enabling tobacco cessation - its holistic effects in managing stress and insomnia associated with abstinence1R33AT012328-01 · under PAR-20-217SALLOUM, RAMZI GEORGEXING, CHENGGUOUNIVERSITY OF FLORIDA, FL$522,987ZAT1
2023Beetroot Juice Supplement for Boosting Mucosal Immunity – The NO Cold Study1R33AT012022-01A1 · under PAR-20-217RITZ, THOMAS EKKEHARDSOUTHERN METHODIST UNIVERSITY, TX$518,775ZAT1
2023Psilocybin and Affective Function in Chronic Lower Back Pain and Depression1R33AT012317-01 · under PAR-20-217FINAN, PATRICKYADEN, DAVID BRYCEJOHNS HOPKINS UNIVERSITY, MD$478,742ZAT1
2020Optimization of Blood Levels of 25(OH)-vitamin D in African Americans1R33AT010637-01A1 · under PAR-18-828JAIN, SUSHIL KLOUISIANA STATE UNIV HSC SHREVEPORT, LA$507,204ZAT1
2017Latiglutenase as a Treatment for Celiac Disease1R33AT009637-01 · under PAR-16-419MURRAY, JOSEPH ASYAGE, JACK A.IMMUNOGENICS, LLC, CA$592,996ZAT1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

PAR-25-270: NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required) | ScienceDex | ConductScience